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Background: Laparoscopic surgery has been shown to provide important advantages in comparison with open
procedures in the treatment of several malignant diseases, such as less perioperative blood loss and faster patient
recovery. It also maintains similar results with regard to tumor resection margins and oncological long-term survival.
In gastric cancer the role of laparoscopic surgery remains unclear.
Current recommended treatment for gastric cancer consists of radical resection of the stomach, with a free margin
of 5 to 6 cm from the tumor, combined with a lymphadenectomy. The extent of the lymphadenectomy is
considered a marker for radicality of surgery and quality of care. Therefore, it is imperative that a novel surgical
technique, such as minimally invasive total gastrectomy, should be non-inferior with regard to radicality of surgery
and lymph node yield.
Methods/Design: The Surgical Techniques, Open versus Minimally invasive gastrectomy After CHemotherapy
(STOMACH) study is a randomized, clinical multicenter trial. All adult patients with primary carcinoma of the
stomach, in which the tumor is considered surgically resectable (T1-3, N0-1, M0) after neo-adjuvant chemotherapy,
are eligible for inclusion and randomization. The primary endpoint is quality of oncological resection, measured by
radicality of surgery and number of retrieved lymph nodes. The pathologist is blinded towards patient allocation.
Secondary outcomes include patient-reported outcomes measures (PROMs) regarding quality of life, postoperative
complications and cost-effectiveness. Based on a non-inferiority model for lymph node yield, with an average lymph
node yield of 20, a non-inferiority margin of −4 and a 90% power to detect non-inferiority, a total of 168 patients
are to be included.
Discussion: The STOMACH trial is a prospective, multicenter, parallel randomized study to define the optimal
surgical strategy in patients with proximal or central gastric cancer after neo-adjuvant therapy: the conventional
‘open’ approach or minimally invasive total gastrectomy.
Trial registration: This trial was registered on 28 April 2014 at Clinicaltrials.gov with the identifier NCT02130726.
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Laparoscopic surgery has been shown to provide import-
ant advantages in comparison with an open approach in
the treatment of gastrointestinal malignant diseases, such
as less perioperative blood loss, faster patient recovery and
shorter hospital stay. It also maintains similar outcomes
with regard to tumor resection margins and oncological
long-term survival [1,2]. In gastric cancer, the role of lap-
aroscopic surgery remains unclear.
The current recommended treatment for gastric can-
cer consists of radical resection of the stomach, with a
free margin of 5 to 6 cm from the tumor, combined with
a lymphadenectomy. The extent of the lymphadenec-
tomy, performed according to the guidelines of the Japa-
nese Gastric Cancer Association, is considered a marker
for radicality of surgery and quality of care [3]. Therefore,
it is imperative that a novel surgical approach such as lap-
aroscopic total gastrectomy should be non-inferior with
regard to radicality of surgery and lymph node yield.
Several studies have focused on laparoscopic versus
open gastrectomy. These studies are predominantly con-
ducted in Asian countries [4,5], where the incidence of
gastric cancer is higher in comparison to Western coun-
tries [6,7]. The screening program in Japan, which started
in 1983, has enabled important advances in the detection
and treatment of early gastric carcinomas in this country
[8]. As such, tumor stages are lower at the time of diagno-
sis compared to Western countries, and it is difficult to
translate the results of Asian studies to a population for
which no screening program exists, and in which the
stages of the tumors at diagnosis are higher [9].
Only a few Western studies, one randomized controlled
trial and some cohort analyses, have been conducted com-
paring laparoscopic and open approaches for gastric can-
cer [10-14]. In the randomized controlled trial by Huscher
et al., they found that laparoscopic partial gastrectomy
showed similar results to open gastrectomy with regards
to quality of oncological resection, as measured by the
number of retrieved lymph nodes, and five-year survival
rate, whereas patient recovery was faster and admission
duration was shorter [10-14]. However, these studies are
small and underpowered and are exceeded by changes in
neo-adjuvant therapies. Further research is indicated in
order to establish the optimal surgical strategy.
Moreover, implementation of neo-adjuvant chemother-
apy is currently used after the outcome of different studies
on this subject [15,16]. Nowadays the use of neo-adjuvant
treatment followed by gastric resection is extensive and
applies in stage Ib to IVa gastric cancer [17]. The effect of
neo-adjuvant chemotherapy on a laparoscopic gastrec-
tomy in comparison with an open resection remains un-
clear. For instance, in rectal and breast cancer, neo-
adjuvant chemotherapy has been associated with response
of the tumor and a lower number of lymph nodes foundin the specimen [18]. In gastric cancer, preoperative
chemotherapy has been associated with a lower number
of tumor-positive lymph nodes, however no difference
in total lymph node yield was reported [19]. In other
series, laparoscopic gastrectomy has shown non-inferior
results with regard to lymph node yield in comparison
to open gastrectomy, but these studies were conducted
before the implementation of neo-adjuvant chemotherapy
[12,20,21]. Moreover, the difficulty of dissection and re-
section, and the quality of a laparoscopically performed
esophagojejunostomy, remains a technical challenge.
Considering all these factors, such as the differences in
populations, the number of retrieved lymph nodes, the
location of lymph nodes in anatomical stations, the in-
creased use of neo-adjuvant chemotherapy and the
technical difficulties derived from the laparoscopic total
gastrectomy, a randomized controlled trial comparing
open and laparoscopic total gastrectomy after neo-
adjuvant therapy is warranted. Such a trial could pro-
vide an answer to the question, ‘Is a minimally invasive




The objective of this study is to establish the optimal
surgical strategy in the treatment of patients with gastric
cancer. The STOMACH trial is a prospective, inter-
national, multicenter, parallel randomized clinical trial.
Patients with gastric cancer selected to undergo a total
gastrectomy, who have received neo-adjuvant chemo-
therapy, are randomized between a conventional ‘open’
and a minimally invasive group.
Endpoints
The primary endpoint is quality of oncological resection
with regard to radicality of surgery and lymph node dis-
section in all the appointed stations. Both the total num-
ber of resected lymph nodes and the resected lymph
node stations will be examined. After surgery, the sur-
geon will attach tags with numbers corresponding with
the dissected lymph node stations to the specimen. This
will allow for a more extensive assessment of the feasi-
bility of minimally invasive versus open resection.
Secondary endpoints include postoperative complica-
tions, which are monitored for 30 days postoperatively.
Overall length of hospital stay and Intensive Care Unit
(ICU) stay will also be recorded. Survival will be moni-
tored for up to three years postoperatively. Quality of life
is assessed with patient-reported outcome measures
(PROM), the Euro-Quality of Life-5D (EQ-5D) ques-
tionnaire, the European Organizaion for Research and
Treatment of Cancer Quality of Life Questionnaire 30
(EORTC-QLQ30 and the Stomach 22 module (STO22).
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tively, five days postoperatively, three months, six months
and one year postoperatively. Cost-effectiveness will be
assessed from a hospital and societal perspective.Power of the study
The number of dissected lymph nodes in gastric cancer
surgery is an important marker for radicality of surgery
and quality of care [22-24]. Therefore the primary out-
come in this study is the number of retrieved lymph
nodes in laparoscopic surgery compared to an open
procedure.
It is anticipated that laparoscopic gastric resection will
show similar surgical resection specimen quality [19],
based on the results of the Dutch Cancer Registry (NKR).
The sample size calculation is set to achieve 90% power
to detect non-inferiority using a one-sided, two-sample
t-test. With a margin of non-inferiority at −4.0 and a
significance level (α) of 0.05, the sample size requires 66
patients to be included per group, with a total sample
size of 132 patients. A non-inferiority margin of −4.0 is
deemed feasible, since the current average lymph node
yield at the VU University Medical Center ((VUmc)
Amsterdam) is around 20, meaning a lymph node yield
of 16 is acceptable.
Since lymph node yield is of interest in cases of radical
resection, further correction is necessary for radicality of
surgery. The NKR showed that a radical resection was
achieved in 79% of patients, although palliative resection
figures are not given separately. After correction for
radicality, a total of 168 patients are to be included. In
other, similar prospective studies, no loss to follow-up
was recorded, therefore we do not take into account a
percentage for loss to follow-up [25,26].Inclusion criteria
All adult patients with primary carcinoma of the stom-
ach, where the tumor is considered surgically resectable
(T1-3, N0-1, M0) after neo-adjuvant chemotherapy, are
eligible. Only patients with an indication for total gas-
trectomy are included, in order to exclude bias due to
different surgical approaches. Written informed consent
is obligatory.Exclusion criteria
Exclusion criteria are previous surgery of the stomach
and patients with a previous history of cancer or pre-
senting with a co-existing cancer. To allow for appropri-
ate inclusion and randomization, patients operated in an
acute setting are excluded. Patients with an American
Society of Anesthesiologists (ASA) classification of four
of higher are excluded.Participating surgeons and clinics
Complication rate, duration of operation and morbidity
can be a result of the learning curve of the operating
surgeon, and this might bias results. In order to prevent
surgeon bias, participating surgeons are to have sufficient
experience in open and minimally invasive total gastrec-
tomy. Based on the literature and the Dutch guidelines for
gastric carcinoma [27,28], it is required that the participat-
ing surgeon has performed at least 20 open and minimally
invasive total gastrectomies.
All surgeons in participating centers have sufficient
prior experience with both open and minimally invasive
gastrectomy. Eight European academic and non-academic
centers will participate in the study: the VU University
Medical Center, Amsterdam; Academisch Medisch
Centrum, Amsterdam; Antoni van Leeuwenhoek Ziekenhuis,
Amsterdam; Universitätsklinikum Carl Gustav Carus,
Dresden; Hospital Universitario del Sureste, Madrid;
Hospital General de Jerez de la Frontera, Cadiz; Salford
Royal NHS Foundation Trust, Manchester and Hospital
Universitario Basurto, Bilbao.Randomization and blinding
Information regarding the study will be provided to the
patient at the outpatient clinic. When informed consent
is obtained, the patient will be randomized at the out-
patient clinic. Randomization occurs via an online mod-
ule. The participating surgeon can login via a secured
module on the STOMACH trial website. Upon filling
out the randomization form, an immediate response is
obtained, containing a code number and the allocated
type of operation.
The study design is unblinded with regard to patient
and physician. The patient will be informed about the
type of procedure they are allocated to. When patients
do not agree to participate in the study they will receive
the standard treatment in the corresponding depart-
ment. The pathologist assessing the specimen is blinded
for the operating technique, since radicality of surgery
and the number of assessed lymph nodes and lymph
node stations is the primary outcome in this trial.Data collection and statistics
Data is collected via a secured Internet module and via
datasheets on paper. A secured online module has been
especially designed for the STOMACH trial, using
OpenClinica, version 3.3. © 2015 OpenClinica, LLC.
Paper datasheets, such as completed questionnaires, will
be sent to the VUmc by mail, where they are kept in a
secured room. Data are collected daily until discharge.
PROMs are collected preoperatively, five days postop-
eratively, at three months, six months and one year
postoperatively.
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data of all included patients, and maintain regular con-
tact with all participating centers. All required parame-
ters will be collected in an SPSS data file, SPSS version
22, IBM statistics®, Chicago, Illinois, USA . Data analysis
will be performed according to the intention-to-treat
principle. Continuous variable will be compared with a
T-test or Mann-Whitney U as appropriate, and frequen-
cies will be compared with a chi-square or the McNemar
analysis as appropriate.Ethics
The study is conducted in accordance with the principles
of the Declaration of Helsinki and ‘good clinical practice’
guidelines. The independent medical ethics committee
of the VUmc (Medisch Ethische Toetsingscommissie
VU Medisch Centrum, Amsterdam, the Netherlands)
has approved the final version of the protocol prior to
the start of the study (approval number: 2014.354 -
NL51293.029.14). Written informed consent will be obtained
from all participating patients. This trial was registered on
28 April 2014 at Clinicaltrials.gov with the trial number
NCT02130726.Figure 1 Overview of placement of trocars in minimally
invasive gastrectomy. 1) laparoscope placement, 2) Nathanson
Hook Liver Retractor, (3 and 4) additional instruments, 5) the incision
(±5 to 6 cm) is performed in order to allow for retrieval of the specimen,
and the wound is protected with an Alexis® wound protector, Applied
Medical Resources Corp, Rancho Santa Margarita, California, USA. Dotted
line portrays open gastrectomy.Surgical technique
Preoperative preparation
All patients will receive the same preoperative prepar-
ation, regardless of allocated treatment. All participating
patients will receive standard preoperative prophylactic
antibiotics consisting of a single dose of cefuroxime at
1,500 mg and a single dose of metronidazole at 500 mg.
Antithrombotic prophylaxis will be administered accord-
ing to local protocol.Open gastrectomy
For the open gastrectomy, the patient is placed in the
supine position. Access to the abdomen is obtained via a
median laparotomy. The Omnitract® system, Omni-tract
Surgical, St Pauls, Minnesota, USA, is placed over the
incision in order to secure vision over the stomach.Minimally invasive gastrectomy
For the minimally invasive gastrectomy, the patient is
placed in the reverse Trendelenburg position and the
legs are abducted. The surgeon is positioned between
the legs of the patient. The first trocar, for the laparo-
scope, is inserted at the umbilicus. After insertion, a
pneumoperitoneum is created. The following trocars are
placed with the aid of the laparoscope. The overview of
trocar placement is depicted in Figure 1. A Nathanson
Hook Liver Retractor® may be placed in order to retract
the liver from the operation area.Gastrectomy
After the placement of trocars or opening of the abdomen,
the abdomen is inspected for signs of tumor progression.
The greater omentum is mobilized and dissected from the
transverse colon. Access to the lesser sac is obtained. The
right gastro-epiploic artery is identified and clipped and
according lymph node stations dissected. This is followed
by further dissection and ligation of the right gastric artery
and harvesting of the hepatic lymph node stations. The
duodenum is dissected up to 5 cm distal to the pylorus,
followed by transection of the duodenum.
Dissection continues with mobilization of the left part
of the stomach. After identification of the left gastric ar-
tery, the artery is clipped and according lymph node sta-
tions are harvested. Further dissection continues towards
the hiatus, where the pericardial lymph nodes are har-
vested. After the gastro-esophageal junction is identified
and dissected, it is transected using a linear stapling de-
vice. With regard to transection, a proximal margin of
6 cm from the tumor is recommended [3]. After en bloc
resection, the specimen is removed, but not yet stored.
After completion of the surgery, the surgeon attaches tags
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allowing for separate analysis of each lymph node station.
Reconstruction occurs with a Roux and Y anastomosis.
First, the jejunum is mobilized upwards in a retrocolic
fashion. Anastomosis between the esophagus and jejunum
is performed. Next, a jejunojejunostomy is fashioned. A
final overview is performed of the abdomen, with control
of hemostasis. Lastly, a silicone drain is placed in the oper-
ated area, if deemed necessary by the operating surgeon,
and the abdomen is closed.
Postoperative management
Irrespective of open or minimally invasive gastrectomy,
patients will receive similar postoperative management.
Depending on local protocol, a nasogastric tube may be
positioned. Oral diet is initiated. Postoperative pain con-
trol consists of patient-controlled analgesia (PCA),
which is monitored daily by an anesthesiologist. PCA
pumps will remain in situ for a maximum of three days.
Patients are encouraged to be out of bed and walking
around the ward, under the guidance of a physiotherap-
ist or nurse. Patients will be discharged when they pass
stool, are able to drink, can walk and are comfortable
with oral analgesia. A delay in discharge due to ‘social’
reasons will be recorded. Follow-up occurs at the out-
patient clinic; patients are seen routinely at three, six
and 12 months postoperatively.
Discussion
Laparoscopic surgery has been shown to provide import-
ant advantages in comparison with open procedures in
surgery of the rectum and colon. Since the first minim-
ally invasive total gastrectomy in 1996 by Azagra et al.
[29], several comparative studies between open and min-
imally invasive approaches of the stomach have been
published. Short-term results show less perioperative
blood loss, faster patient recovery and earlier discharge
from the hospital. One study reported long-term results
with similar survival and disease-free survival rates in
the open and minimally invasive approach [10].
Most studies are conducted in Asian countries, where
a screening program has enabled early detection and
treatment. The results of these studies cannot be trans-
lated to the Western population. Western studies have
deemed minimally invasive gastrectomy to be feasible,
although the numbers are small and the studies often
underpowered. Furthermore, these studies were con-
ducted before the implementation of neo-adjuvant ther-
apy. Currently, in the Netherlands, less than 10% of
patients are operated on via a minimally invasive ap-
proach [30]. A prospective, randomized clinical trial is
considered necessary in order to establish the optimal
surgical technique in gastric cancer: open or minimally
invasive gastrectomy.Trial status
The Scientific Research Committee of the Cancer Centre
Amsterdam, NL, approved the design of the STOMACH
trial. The Medical Ethical committee of the VUmc has
approved the protocol (approval number: 2014.354 -
NL51293.029). The trial is open for recruitment since
January 2015.
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